CClinicalTrials.gg
CompletedNCT04393623SERAUpdated Feb 27, 2026Results posted

Stress, Emotion Regulation, and Alcohol in Women Veterans

An interventional study of Cognitive Reappraisal and Psychoeducation in Alcohol Use Disorder and Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of the study "Stress, Emotion Regulation, and Alcohol in Women Veterans" is to learn about the effects of negative emotion and stress on behavior (including alcohol use) among women Veterans, including women with and without posttraumatic stress disorder. Additionally, the study looks at whether a woman's use of emotion regulation techniques changes the association between stress or negative emotion and behavior. Lastly, the study examines how women's reactions to stress, and the effects of stress, vary across the menstrual cycle - depending on the level of circulating hormones.

Read the detailed description

Aims for the current study are two-fold: 1. conduct a randomized trial testing the effects of an emotion regulation skill (cognitive reappraisal) on stress-induced drinking among women with alcohol misuse and varying levels of co-occurring PTSD; 2. examine whether progesterone levels and/or severity of co-occurring PTSD - factors which impact women's stress reactivity and emotion regulation - moderate the effectiveness of the cognitive reappraisal in reducing stress-induced drinking.

The proposed study will combine experimental, in-person sessions with daily self-report data from the Veterans to assess the effect of cognitive reappraisal on alcohol craving, cognitive (inhibitory) control, physiological arousal (HRV), and alcohol use. Participation will take place across a period of at least 35 days, to encompass an entire menstrual cycle. All participants complete all sections of the study - the experimental sessions and the longitudinal (35-day) data collection.

02

Conditions studied

  • Alcohol Use Disorder
  • Post Traumatic Stress Disorder

Keywords

  • Alcohol Use Disorder
  • Women Veterans
  • Endocrinology
  • Cognitive Reappraisal
  • Microintervention
  • Progesterone
  • Posttraumatic Stress Disorder
  • Psychophysiology
  • Heart Rate Variability
03

In context

Alcoholism

1,606 studies on the registry are indexed under Alcoholism; 329 are open to participants now.

This study's enrollment of 81 is close to the median of 87 across 1,371 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,733 studies on the registry; 396 are open to participants now.

Of its 206 completed or terminated interventional studies of FDA-regulated products, 180 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Current alcohol misuse, defined as scoring 3 or higher on the AUDIT-C
  • If using other illicit substances, alcohol is their primary substance of use
  • Alcohol use in the past 45 days
  • Able to write and speak in English
  • Served in the U.S. Military
  • Willing to provide blood samples at laboratory sessions to assay hormone levels and take urine ovulation tests at home

Exclusion criteria

Exclusion Criteria:

  • Psychotic symptoms or uncontrolled Bipolar Disorder (screened for during session 1 using SCID-5 screening modules)
  • Brain damage or were in an accident that affects ability to complete the computerized task
  • Current (past 3 months) active suicidal ideation or intent
  • Current pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Cognitive Reappraisal Microintervention

    The CR microintervention (session 1) is drawn from Barlow \& colleagues empirically supported treatment for emotional disorders (the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders). The microintervention consist of four sections: (1) Introduction to cognitive appraisal; (2) Introducing the idea of "thinking traps" that prevent reappraisal and maintain negative emotion; (3) Describing cognitive reappraisal as a strategy that can help the participant "get out" of such thinking traps; (4) Providing an example of this process (situation\> negative appraisal \> negative emotion \> thinking trap \> opportunity for cognitive reappraisal) and have participants provide a personalized example.

    Behavioral: Cognitive Reappraisal

  • Active comparator
    Psychoeducation (Control)

    The manualized psychoeducational control module, serving as an attentional control, is derived from two sources: 1. The first session of the Women's Health Education Manual, which provides psychoeducation about the basic body systems and their function, with focus on components of the immune system and 2. Fact sheets published by the American College of Obstetricians and Gynecologists(ACOG), providing female-specific facts about cancer and heart health. None of this psychoeducation discusses potential relevancy of alcohol use, nor will any behavior changes be suggested during the control microintervention.

    Behavioral: Psychoeducation

Interventions

  • BehavioralCognitive Reappraisal

    This cognitive reappraisal microintervention lasts 45-60 minutes.

  • BehavioralPsychoeducation

    This psychoeducational microintervention lasts 45-60 minutes.

06

What researchers measure

Primary outcomes

  1. Change in Alcohol Craving During Experimental Sessions

    Craving will be measured via the Alcohol Craving Questionnaire - Short Form (ACQ-SF). The ACQ-SF comprises 12 items and is used to assess alcohol cravings among alcohol users in the current moment. Participants are asked to rate how much they agree or disagree with each statement, each regarding how they feel or think about alcohol in the moment. Each item is scored on a 7-point Likert scale that reflects their agreement on a scale of "strongly disagree" to "strongly agree". Total score is an average of responses to each of the 12 items with a range of scores from 1.00-7.00; A higher total score reflects higher craving for alcohol (worse clinical outcome), and a lower score reflects lower craving for alcohol (better clinical outcome).

    Time frame: Outcomes are measured 3 times during the experimental session to examine change: At the start of the session (Baseline), after a 6-minute stress induction, and after using cognitive reappraisal (or sitting quietly, if in the control) for 6 minutes.

  2. Change in Heart Rate Variability (HRV) During Experimental Sessions

    Heart rate variability (HRV), a physiological measure of arousal and shown to be a measure of stress reactivity and impacted by successful emotion regulation, will be assessed with a Biopac MP160 data acquisition unit with an ECG amplifier that allows for the measurement of HRV.

    Time frame: Outcomes are measured 3 times during the experimental session to examine change: At start of the session (5 minute baseline), during a 6-minute stress induction, and for 5 minutes after using cognitive reappraisal (or sitting quietly, if in the control).

  3. Change in Frequency of Alcohol Use Prior to and Through Study Completion

    The Alcohol Timeline Follow Back (TLFB) assesses frequency/quantity of drinking. The TLFB will be used at all laboratory sessions to fill in any potentially missing data from the daily logs

    Time frame: Baseline was measured retrospectively for 45 days prior to study enrollment. Post was measured from baseline through study completion, up to 75 days

  4. Change in Intensity of Alcohol Use Prior to and Through Study Completion

    The Alcohol Timeline Follow Back (TLFB) assesses frequency/quantity of drinking. The TLFB will be used at all laboratory sessions to fill in any potentially missing data from the daily logs

    Time frame: Baseline was measured retrospectively for 45 days prior to study enrollment. Post was measured from baseline through study completion, up to 75 days

07

Results

Posted Feb 27, 2026
Limitations and caveats
The results reported here reflect the main effects of the intervention condition (Cognitive Reappraisal versus Control condition) on outcome measures assessed in the laboratory and in daily life during study participation. Secondary analyses of study data indicate that severity of Alcohol Use Disorder may impact condition effects, and therefore will be examined in future analyses. Broadening of study inclusion and exclusion criteria during the study has elicited additional analyses.

Participant flow

Participants were women recruited from two sources: 1. Department of Veteran Affairs Medical Center and 2. recruited from the general population/surrounding community. All participants were recruited in the Northeast region of the US.

Participant flow — Overall Study
MilestoneCognitive Reappraisal MicrointerventionPsychoeducation (Control)
Started3839
Session 2 (intervention)3436
Session 3 (experimental)3234
Completed3434
Not completed45
Withdrew: Lost to follow-up45

Outcome measures

PrimaryChange in Alcohol Craving During Experimental Sessions

Craving will be measured via the Alcohol Craving Questionnaire - Short Form (ACQ-SF). The ACQ-SF comprises 12 items and is used to assess alcohol cravings among alcohol users in the current moment. Participants are asked to rate how much they agree or disagree with each statement, each regarding how they feel or think about alcohol in the moment. Each item is scored on a 7-point Likert scale that reflects their agreement on a scale of "strongly disagree" to "strongly agree". Total score is an average of responses to each of the 12 items with a range of scores from 1.00-7.00; A higher total score reflects higher craving for alcohol (worse clinical outcome), and a lower score reflects lower craving for alcohol (better clinical outcome).

Time frame:
Outcomes are measured 3 times during the experimental session to examine change: At the start of the session (Baseline), after a 6-minute stress induction, and after using cognitive reappraisal (or sitting quietly, if in the control) for 6 minutes.
Reported as:
Mean · Units on a Scale
Change in Alcohol Craving During Experimental Sessions
Units on a ScaleCognitive Reappraisal MicrointerventionPsychoeducation (Control)
ACQ score - Baseline (Range: 1-7)2.87 ± 0.782.97 ± 0.69
ACQ Score - Post-Stress Induction (Range: 1-7)3.18 ± 1.113.22 ± 0.86
ACQ Score - Post Cognitive Reappraisal/Sitting Quietly (Range: 1-7)3.27 ± 1.013.24 ± 1.02
Statistical analysis
  • Cognitive Reappraisal Microintervention vs Psychoeducation (Control) · Mixed Models Analysis · p = .94 · Wilks' lambda: .998
PrimaryChange in Heart Rate Variability (HRV) During Experimental Sessions

Heart rate variability (HRV), a physiological measure of arousal and shown to be a measure of stress reactivity and impacted by successful emotion regulation, will be assessed with a Biopac MP160 data acquisition unit with an ECG amplifier that allows for the measurement of HRV.

Time frame:
Outcomes are measured 3 times during the experimental session to examine change: At start of the session (5 minute baseline), during a 6-minute stress induction, and for 5 minutes after using cognitive reappraisal (or sitting quietly, if in the control).
Reported as:
Mean · milliseconds (ms)
Change in Heart Rate Variability (HRV) During Experimental Sessions
milliseconds (ms)Cognitive Reappraisal MicrointerventionPsychoeducation (Control)
RMSSD - Baseline47.20 ± 48.9636.64 ± 22.48
RMSSD - Post-Stress Induction108.33 ± 246.5734.82 ± 23.23
RMSSD - Post Cognitive Reappraisal/Sitting Quietly62.69 ± 91.6040.68 ± 30.30
Statistical analysis
  • Cognitive Reappraisal Microintervention vs Psychoeducation (Control) · Mixed Models Analysis · Wilks' lambda: .912
PrimaryChange in Frequency of Alcohol Use Prior to and Through Study Completion

The Alcohol Timeline Follow Back (TLFB) assesses frequency/quantity of drinking. The TLFB will be used at all laboratory sessions to fill in any potentially missing data from the daily logs

Time frame:
Baseline was measured retrospectively for 45 days prior to study enrollment. Post was measured from baseline through study completion, up to 75 days
Reported as:
Mean · Percent Days Drinking (PDD)
Change in Frequency of Alcohol Use Prior to and Through Study Completion
Percent Days Drinking (PDD)Cognitive Reappraisal MicrointerventionPsychoeducation (Control)
Percent Days Drinking (PDD) - Baseline (45 days prior to study enrollment)46.49 ± 29.8245.91 ± 27.74
Percent Days Drinking (PDD) - Post (From Baseline through Study Completion)54.57 ± 30.2447.15 ± 28.14
Statistical analysis
  • Cognitive Reappraisal Microintervention vs Psychoeducation (Control) · Mixed Models Analysis · Wilks' lambda: .996
PrimaryChange in Intensity of Alcohol Use Prior to and Through Study Completion

The Alcohol Timeline Follow Back (TLFB) assesses frequency/quantity of drinking. The TLFB will be used at all laboratory sessions to fill in any potentially missing data from the daily logs

Time frame:
Baseline was measured retrospectively for 45 days prior to study enrollment. Post was measured from baseline through study completion, up to 75 days
Reported as:
Mean · Mean Drinks per Drinking Day (MDPDD)
Change in Intensity of Alcohol Use Prior to and Through Study Completion
Mean Drinks per Drinking Day (MDPDD)Cognitive Reappraisal MicrointerventionPsychoeducation (Control)
MDPDD - Baseline (45 days prior to study enrollment)2.98 ± 1.742.42 ± 1.12
MDPDD - Post (From Baseline through Study Completion)2.63 ± 1.182.37 ± 1.12
Statistical analysis
  • Cognitive Reappraisal Microintervention vs Psychoeducation (Control) · Mixed Models Analysis · Wilks' lambda: 0.978

Adverse events

Collected over From enrollment to the end of study participation, up to 75 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitive Reappraisal Microintervention0/38 (0%)0/38 (0%)0/38 (0%)
Psychoeducation (Control)0/39 (0%)0/39 (0%)0/39 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cognitive Reappraisal MicrointerventionPsychoeducation (Control)Total
Mean41 ± 1041 ± 1441 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Cognitive Reappraisal MicrointerventionPsychoeducation (Control)Total
Female383977
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cognitive Reappraisal MicrointerventionPsychoeducation (Control)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American224
White343670
More than one race202
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cognitive Reappraisal MicrointerventionPsychoeducation (Control)Total
Hispanic or Latino415
Not Hispanic or Latino343872
Unknown or Not Reported000
Veteran Status
Veteran Status(Participants)Cognitive Reappraisal MicrointerventionPsychoeducation (Control)Total
Veterans313061
Non-Veterans7916
08

Study locations

1 site
  • VA Central Western Massachusetts Healthcare System, Leeds, MA
    Leeds, Massachusetts 01053-9764, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 22, 2022
  • Informed consent form · Apr 4, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04393623
Lead sponsor
VA Office of Research and Development
Responsible party
Sponsor
First posted
May 19, 2020
Start date
Nov 1, 2020
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Results posted
Feb 27, 2026
Last update
Feb 27, 2026

Study contacts

Cathryn Glanton Holzhauer, PhD
principal investigator · VA Central Western Massachusetts Healthcare System, Leeds, MA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion